Roles of spike protein in the pathogenesis of SARS coronavirus.
Identifieur interne : 001800 ( PubMed/Checkpoint ); précédent : 001799; suivant : 001801Roles of spike protein in the pathogenesis of SARS coronavirus.
Auteurs : D Y Jin [République populaire de Chine] ; B J ZhengSource :
- Hong Kong medical journal = Xianggang yi xue za zhi [ 1024-2708 ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Cellules Vero, Cellules cultivées, Facteur Xa (métabolisme), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (métabolisme), Inhibiteurs de protéases (pharmacologie), Pliage des protéines (), Protéines de l'enveloppe virale (métabolisme), Pénétration virale (), Syndrome respiratoire aigu sévère (), Systèmes de délivrance de médicaments, Virus du SRAS (), Virus du SRAS (métabolisme), eIF-2 Kinase (métabolisme).
- MESH :
- métabolisme : Facteur Xa, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus du SRAS, eIF-2 Kinase.
- pharmacologie : Inhibiteurs de protéases.
- Animaux, Cellules Vero, Cellules cultivées, Glycoprotéine de spicule des coronavirus, Pliage des protéines, Pénétration virale, Syndrome respiratoire aigu sévère, Systèmes de délivrance de médicaments, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Cells, Cultured, Chlorocebus aethiops, Drug Delivery Systems, Factor Xa (metabolism), Membrane Glycoproteins (metabolism), Protease Inhibitors (pharmacology), Protein Folding (drug effects), SARS Virus (drug effects), SARS Virus (metabolism), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Vero Cells, Viral Envelope Proteins (metabolism), Virus Internalization (drug effects), eIF-2 Kinase (metabolism).
- MESH :
- chemical , metabolism : Factor Xa, Membrane Glycoproteins, Viral Envelope Proteins, eIF-2 Kinase.
- chemical , pharmacology : Protease Inhibitors.
- drug effects : Protein Folding, SARS Virus, Virus Internalization.
- metabolism : SARS Virus.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Cells, Cultured, Chlorocebus aethiops, Drug Delivery Systems, Spike Glycoprotein, Coronavirus, Vero Cells.
Abstract
1. Infection with SARS coronavirus (SARS-CoV) induces a cellular stress condition known as the unfolded protein response (UPR). UPR induction is mediated primarily by viral spike (S) protein. The modulation of UPR by S protein involves activation of PERK protein kinase. Other branches of the UPR pathways controlled by IRE1 and ATF6 proteins, respectively, are not involved. 2. The protease inhibitor Ben-HCl effectively suppresses SARS-CoV infection by blocking virus entry. Viral infectivity is associated with the cleavage of S protein by the cellular protease factor Xa. 3. Two new aspects of the interaction between SARS-CoV S protein and the cell have been defined. These have important implications in the pathogenesis of SARS, providing opportunities for developing vaccines and antivirals against SARS-CoV. 4. Counteracting the UPR and targeting the cleavage of S protein with small molecule pharmaceutical agents represent two new anti-SARS-CoV strategies. 5. The receptor-binding domain of S protein delivered via adeno-associated virus can efficiently induce mucosal immunity and provide long-term protection against SARS-CoV infection.
PubMed: 19258633
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19258633Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Roles of spike protein in the pathogenesis of SARS coronavirus.</title><author><name sortKey="Jin, D Y" sort="Jin, D Y" uniqKey="Jin D" first="D Y" last="Jin">D Y Jin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China. dyjin@ hkucc.hku.hk</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19258633</idno><idno type="pmid">19258633</idno><idno type="wicri:Area/PubMed/Corpus">001829</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001829</idno><idno type="wicri:Area/PubMed/Curation">001829</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001829</idno><idno type="wicri:Area/PubMed/Checkpoint">001800</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001800</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Roles of spike protein in the pathogenesis of SARS coronavirus.</title><author><name sortKey="Jin, D Y" sort="Jin, D Y" uniqKey="Jin D" first="D Y" last="Jin">D Y Jin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China. dyjin@ hkucc.hku.hk</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR</wicri:regionArea><wicri:noRegion>Hong Kong SAR</wicri:noRegion></affiliation></author><author><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></author></analytic><series><title level="j">Hong Kong medical journal = Xianggang yi xue za zhi</title><idno type="ISSN">1024-2708</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Chlorocebus aethiops</term><term>Drug Delivery Systems</term><term>Factor Xa (metabolism)</term><term>Membrane Glycoproteins (metabolism)</term><term>Protease Inhibitors (pharmacology)</term><term>Protein Folding (drug effects)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (metabolism)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vero Cells</term><term>Viral Envelope Proteins (metabolism)</term><term>Virus Internalization (drug effects)</term><term>eIF-2 Kinase (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Cellules cultivées</term><term>Facteur Xa (métabolisme)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Pliage des protéines ()</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Pénétration virale ()</term><term>Syndrome respiratoire aigu sévère ()</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS ()</term><term>Virus du SRAS (métabolisme)</term><term>eIF-2 Kinase (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Factor Xa</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term><term>eIF-2 Kinase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Protein Folding</term><term>SARS Virus</term><term>Virus Internalization</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Facteur Xa</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Virus du SRAS</term><term>eIF-2 Kinase</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Inhibiteurs de protéases</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cells, Cultured</term><term>Chlorocebus aethiops</term><term>Drug Delivery Systems</term><term>Spike Glycoprotein, Coronavirus</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Cellules cultivées</term><term>Glycoprotéine de spicule des coronavirus</term><term>Pliage des protéines</term><term>Pénétration virale</term><term>Syndrome respiratoire aigu sévère</term><term>Systèmes de délivrance de médicaments</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. Infection with SARS coronavirus (SARS-CoV) induces a cellular stress condition known as the unfolded protein response (UPR). UPR induction is mediated primarily by viral spike (S) protein. The modulation of UPR by S protein involves activation of PERK protein kinase. Other branches of the UPR pathways controlled by IRE1 and ATF6 proteins, respectively, are not involved. 2. The protease inhibitor Ben-HCl effectively suppresses SARS-CoV infection by blocking virus entry. Viral infectivity is associated with the cleavage of S protein by the cellular protease factor Xa. 3. Two new aspects of the interaction between SARS-CoV S protein and the cell have been defined. These have important implications in the pathogenesis of SARS, providing opportunities for developing vaccines and antivirals against SARS-CoV. 4. Counteracting the UPR and targeting the cleavage of S protein with small molecule pharmaceutical agents represent two new anti-SARS-CoV strategies. 5. The receptor-binding domain of S protein delivered via adeno-associated virus can efficiently induce mucosal immunity and provide long-term protection against SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19258633</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1024-2708</ISSN><JournalIssue CitedMedium="Internet"><Volume>15 Suppl 2</Volume><PubDate><Year>2009</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Hong Kong medical journal = Xianggang yi xue za zhi</Title><ISOAbbreviation>Hong Kong Med J</ISOAbbreviation></Journal><ArticleTitle>Roles of spike protein in the pathogenesis of SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>37-40</MedlinePgn></Pagination><Abstract><AbstractText>1. Infection with SARS coronavirus (SARS-CoV) induces a cellular stress condition known as the unfolded protein response (UPR). UPR induction is mediated primarily by viral spike (S) protein. The modulation of UPR by S protein involves activation of PERK protein kinase. Other branches of the UPR pathways controlled by IRE1 and ATF6 proteins, respectively, are not involved. 2. The protease inhibitor Ben-HCl effectively suppresses SARS-CoV infection by blocking virus entry. Viral infectivity is associated with the cleavage of S protein by the cellular protease factor Xa. 3. Two new aspects of the interaction between SARS-CoV S protein and the cell have been defined. These have important implications in the pathogenesis of SARS, providing opportunities for developing vaccines and antivirals against SARS-CoV. 4. Counteracting the UPR and targeting the cleavage of S protein with small molecule pharmaceutical agents represent two new anti-SARS-CoV strategies. 5. The receptor-binding domain of S protein delivered via adeno-associated virus can efficiently induce mucosal immunity and provide long-term protection against SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>D Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, The University of Hong Kong, 21 Sassoon Road, Hong Kong SAR, China. dyjin@ hkucc.hku.hk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Hong Kong Med J</MedlineTA><NlmUniqueID>9512509</NlmUniqueID><ISSNLinking>1024-2708</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C117035">PERK kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D019892">eIF-2 Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.6</RegistryNumber><NameOfSubstance UI="D015951">Factor Xa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015951" MajorTopicYN="N">Factor Xa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019892" MajorTopicYN="N">eIF-2 Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19258633</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Zheng, B J" sort="Zheng, B J" uniqKey="Zheng B" first="B J" last="Zheng">B J Zheng</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Jin, D Y" sort="Jin, D Y" uniqKey="Jin D" first="D Y" last="Jin">D Y Jin</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001800 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001800 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:19258633
|texte= Roles of spike protein in the pathogenesis of SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19258633" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |